CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas
- PMID: 36716922
- DOI: 10.1016/j.jid.2023.01.009
CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas
Comment in
-
CD38 Targeting Holds Potential for the Treatment of Aggressive Refractory Cutaneous T-Cell Lymphomas.J Invest Dermatol. 2023 Jul;143(7):1122-1126. doi: 10.1016/j.jid.2023.02.011. Epub 2023 Mar 16. J Invest Dermatol. 2023. PMID: 36933969 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials